Physician profile
Christopher W Grayson
NPI 1528294618
$348,515.73
in general payments reported to CMS, 2019-2025
30 companies · $98K in 2025
The $98K reported for 2025 was more than what 97% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,404 · 2020: $457 · 2021: $42K · 2022: $67K · 2023: $93K · 2024: $44K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $167K · Travel and Lodging: $37K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $167,100.00 |
| Travel and Lodging | $36,720.77 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $20,250.00 |
| Food and Beverage | $11,134.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $251,586.77 | 2019-2025 | Mako, Insignia, Aequalis |
| Ortho Development Corporation | $61,902.20 | 2021-2025 | |
| Linkbio Corp | $23,795.68 | 2024-2025 | |
| Osteoremedies, LLC | $4,364.63 | 2020-2025 | Osteoboost Select 10cc, Remedy Spectrum Gv Spacer, Remedy Spacer |
| Zimmer Biomet Holdings, INC. | $1,488.68 | 2019-2025 | Persona, Mymobility Platform, Rosa |
| Kci USA, INC. | $883.56 | 2019 | |
| Pacira Therapeutics, INC. | $520.18 | 2021 | |
| Medacta USA, INC. | $488.80 | 2023-2024 | Gmk Sphere |
| Innovation Technologies INC | $445.80 | 2021-2025 | Irrisept |
| Depuy Synthes Sales INC. | $418.07 | 2022-2024 | Orthovisc, Monovisc |
| Encore Medical, LP | $397.03 | 2019-2023 | Djo Surgical |
| Biocomposites INC | $352.04 | 2019-2022 | |
| Smith+Nephew, INC. | $305.73 | 2019-2025 | Pico 14, Legion Revision, Journey II |
| Next Science LLC | $233.79 | 2022-2023 | Surgx, Blastx, Xperience |
| Sanara Medtech INC. | $180.99 | 2023 | Celleraterx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $166.65 | 2019-2021 | |
| Maxx Orthopedics, INC. | $152.59 | 2023 | |
| Peter Brasseler Holdings, LLC | $128.17 | 2022 | |
| Omnilife Science, INC | $109.42 | 2021 | |
| Illuminoss Medical, INC. | $102.11 | 2023 | Photodynamic Bone Stabilization Procedure Pack |
| Solventum Corporation | $98.98 | 2024 | Prevena |
| Onkos Surgical, INC. | $94.67 | 2021 | |
| Amgen INC. | $92.02 | 2019 | |
| Horizon Therapeutics Plc | $81.04 | 2019-2021 | |
| Heron Therapeutics, INC. | $32.86 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $29.30 | 2020-2022 | |
| Coastal Medical Technologies LLC | $23.03 | 2025 | |
| Acumed LLC | $16.15 | 2025 | Acumed, Osteomed |
| Bioventus LLC | $13.53 | 2019 | |
| Fidia Pharma USA INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Grayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.